Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma [Phase 1]
Pfizer's Phase I trial of the oral BRAF inhibitor LGX818 in adults with BRAF-mutant melanoma has completed and posted results. The study als…
-
CLINICAL_TRIALS research · 2024-10-26Clinical Trial Update: NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma [Phase 2]
A Phase 2 trial, NeoLIPA, is evaluating neoadjuvant LTX-315 in combination with pembrolizumab for resectable stage III/IV melanoma and is cu…
-
CLINICAL_TRIALS research · 2024-10-26Clinical Trial Update: Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients [Phase 2]
Phase 2 clinical trial evaluating intratumoral L19IL2 or L19TNF or L19IL2/L19TNF in combination with pembrolizumab for unresectable melanoma…
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer [Phase 1]
This Phase 1 trial update reports termination of the INBRX-105 in combination with pembrolizumab across multiple solid tumors, including hea…
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab [Phase 2]
Phase 2 study evaluating Vidutolimod (CMP-001) in combination with Nivolumab versus Nivolumab alone in melanoma has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-10-18Clinical Trial Update: Biomarkers in Immunotherapy of Melanoma [NA]
A clinical trial update on biomarker research for immunotherapy in metastatic melanoma, including analyses of the gastrointestinal microbiom…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: Milademetan in Advanced/Metastatic Solid Tumors [Phase 2]
A Phase 2 trial of milademetan in advanced or metastatic solid tumors was terminated, with results posted in October 2024.
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]
This Phase 1 trial assessed the combination of onalespib with dabrafenib and trametinib in patients with BRAF-mutant melanoma or metastatic/…
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy [NA]
A clinical trial update noting recruitment for a study evaluating telemonitoring to manage side effects in patients with melanoma, lung canc…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: AI Augmented Training for Skin Specialists [NA]
A completed clinical trial sponsored by Herlev Hospital evaluating AI-augmented training for skin specialists in diagnosing melanoma and oth…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients [NA]
A completed clinical trial investigated how acute and chronic exercise affects myeloid-derived suppressor cells in patients with melanoma.
-
CLINICAL_TRIALS research · 2024-10-10Clinical Trial Update: Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma [NA]
A completed preclinical study using tumor replicates in an avian embryo to model the effects of BRAF inhibitors and MEK inhibitors in BRAF-m…
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors [Phase 2]
Phase 2 trial evaluating rigosertib plus pembrolizumab in unresectable/metastatic melanoma refractory to PD-1 inhibitors; the study is curre…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma [Phase 2]
Phase II trial evaluating adding tocilizumab to ipilimumab and nivolumab for unresectable stage III/IV melanoma. Results were posted on 2024…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) [Phase 2]
A Phase 2 study evaluating the efficacy and safety of combining lenvatinib with pembrolizumab in patients with advanced melanoma previously …
-
CLINICAL_TRIALS trial_result · 2024-10-08Clinical Trial Update: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma [Phase 2]
A Phase 2 clinical trial evaluating a combination of CD8+ antigen-specific T cells with cyclophosphamide, aldesleukin, and ipilimumab for me…
-
CLINICAL_TRIALS trial_result · 2024-10-08Clinical Trial Update: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma [Phase 1, Phase 2]
Phase 1/2 study evaluating autologous genetically modified lymphocytes followed by Aldesleukin in patients with stage III or metastatic mela…
-
CLINICAL_TRIALS trial_result · 2024-10-08Clinical Trial Update: Safety and Avoidance of Futile Excisions Through Skin Tele-triage
Completed clinical trial evaluating skin tele-triage to reduce futile excisions for melanoma, with aims to improve safety and resource use.
-
CLINICAL_TRIALS research · 2024-10-04Clinical Trial Update: Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
This clinical trial update describes a study evaluating skin health and quality of life in patients receiving anti-PD-1/PD-L1/CTLA-4 inhibit…
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma [Phase 1]
Phase 1 study evaluating the safety and therapeutic activity of RO6874281 in combination with pembrolizumab for advanced or metastatic melan…
-
CLINICAL_TRIALS trial_result · 2024-10-02Clinical Trial Update: Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma [Phase 2]
A Phase 2 trial evaluating an anti-PD-1 antibody in combination with high-dose interleukin-2 for metastatic melanoma has been terminated, wi…
-
CLINICAL_TRIALS research · 2024-10-02Clinical Trial Update: Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies [Phase 1, Phase 2]
This clinical trial update describes ongoing Phase 1/2 evaluation of NGM707 as a monotherapy and in combination with pembrolizumab in advanc…
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults
This clinical trial update describes an AI-based approach for early diagnosis and risk prediction of melanoma in children, adolescents, and …
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors [Phase 1]
Phase 1 pharmacokinetic drug-drug interaction study evaluating encorafenib and binimetinib on probe drugs in patients with BRAF V600-mutant …
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting [Phase 2]
Phase 2 trial evaluating the combination of nivolumab and relatlimab in metastatic melanoma patients who have not received prior immunothera…